{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:47:05Z","timestamp":1785883625955,"version":"3.56.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41440-026-02702-9","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:20:12Z","timestamp":1781061612000},"page":"2386-2398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A modifiable driver of dementia: cognitive impairment in primary aldosteronism"],"prefix":"10.1038","volume":"49","author":[{"given":"Ying-Ying","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ge","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2702_CR1","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3\u201317."},{"key":"2702_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ajh\/hpac012","volume":"35","author":"JW Funder","year":"2022","unstructured":"Funder JW. Primary aldosteronism: imaging vs. lateralization. Am J Hypertens. 2022;35:512\u20133.","journal-title":"Am J Hypertens"},{"key":"2702_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030142","volume":"13","author":"JM Brown","year":"2024","unstructured":"Brown JM. Adverse effects of aldosterone: beyond blood pressure. J Am Heart Assoc. 2024;13:e030142.","journal-title":"J Am Heart Assoc"},{"key":"2702_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","volume":"86","author":"J Ibarrola","year":"2024","unstructured":"Ibarrola J, Jaffe IZ. The mineralocorticoid receptor in the vasculature: friend or foe? Annu Rev Physiol. 2024;86:49\u201370.","journal-title":"Annu Rev Physiol"},{"key":"2702_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1919\u201328.","journal-title":"J Hypertens"},{"key":"2702_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41440-024-01703-w","volume":"47","author":"SS Park","year":"2024","unstructured":"Park SS, Ahn CH, Kim SW, Koh JM, Lee SH, Kim JH. Temporal trends in clinical features of patients with primary aldosteronism over 20 years. Hypertens Res. 2024;47:2019\u201328.","journal-title":"Hypertens Res"},{"key":"2702_CR7","doi-asserted-by":"publisher","first-page":"e788","DOI":"10.1210\/clinem\/dgad520","volume":"109","author":"SS Park","year":"2024","unstructured":"Park SS, Ahn CH, Kim SW, Yoon JW, Kim JH. Subtype-specific body composition and metabolic risk in patients with primary aldosteronism. J Clin Endocrinol Metab. 2024;109:e788\u2013e98.","journal-title":"J Clin Endocrinol Metab"},{"key":"2702_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572\u2013628.","journal-title":"Lancet"},{"key":"2702_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13195-023-01274-x","volume":"15","author":"N Hong","year":"2023","unstructured":"Hong N, Kim KJ, Yu MH, Jeong SH, Lee S, Lim JS, et al. Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study. Alzheimers Res Ther. 2023;15:136.","journal-title":"Alzheimers Res Ther"},{"key":"2702_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1872214810666160809113021","volume":"10","author":"G Bernini","year":"2016","unstructured":"Bernini G, Tric\u00f2 D. Cushing\u2019s syndrome and steroid dementia. Recent Pat Endocr Metab Immune Drug Discov. 2016;10:50\u201355.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"2702_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3928\/15428877-20070501-12","volume":"38","author":"S Kutluhan","year":"2007","unstructured":"Kutluhan S, Kilbas S, Demirci S, Ceki\u00e7 O, Bardak Y, Akhan G. Pheochromocytoma presenting with bithalamic infarction, dementia, and increased intraocular pressure. Ophthalmic Surg Lasers Imaging. 2007;38:245\u20137.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"2702_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12020-021-02920-w","volume":"75","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Li N, Liu Y, Wang M, Heizhati M, Zhu Q, et al. Plasma aldosterone concentration is associated with white matter lesions in patients with primary aldosteronism. Endocrine. 2022;75:889\u201398.","journal-title":"Endocrine"},{"key":"2702_CR13","doi-asserted-by":"publisher","unstructured":"Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2025:dgaf284. https:\/\/doi.org\/10.1210\/clinem\/dgaf284.","DOI":"10.1210\/clinem\/dgaf284"},{"key":"2702_CR14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3803\/EnM.2023.1789","volume":"38","author":"J Ha","year":"2023","unstructured":"Ha J, Park JH, Kim KJ, Kim JH, Jung KY, Lee J, et al. 2023 Korean Endocrine Society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab. 2023;38:597\u2013618.","journal-title":"Endocrinol Metab"},{"key":"2702_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12020-024-03751-1","volume":"85","author":"M Araujo-Castro","year":"2024","unstructured":"Araujo-Castro M, Ruiz-S\u00e1nchez JG, Parra Ram\u00edrez P, Mart\u00edn Rojas-Marcos P, Aguilera-Saborido A, G\u00f3mez Cerezo JF, et al. Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 2024;85:99\u2013121.","journal-title":"Endocrine"},{"key":"2702_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1097\/HJH.0000000000003822","volume":"42","author":"JG Ruiz-Sanchez","year":"2024","unstructured":"Ruiz-Sanchez JG, Fernandez Sanchez \u00c1, Cardenas-Salas J, Fernandez-Cagigao Y, Alegre Bellassai ER, Rossello MG, et al. Primary aldosteronism prevalence enhanced by strict adherence to 2016 Endocrine Society guidelines: insights from an endocrine hypertension unit. J Hypertens. 2024;42:1813\u201322.","journal-title":"J Hypertens"},{"key":"2702_CR17","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1210\/en.2017-00637","volume":"158","author":"L Aragao-Santiago","year":"2017","unstructured":"Aragao-Santiago L, Gomez-Sanchez CE, Mulatero P, Spyroglou A, Reincke M, Williams TA. Mouse models of primary aldosteronism: from physiology to pathophysiology. Endocrinology. 2017;158:4129\u201338.","journal-title":"Endocrinology"},{"key":"2702_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1210\/en.2010-1081","volume":"152","author":"A Spyroglou","year":"2011","unstructured":"Spyroglou A, Wagner S, Gomez-Sanchez C, Rathkolb B, Wolf E, Manolopoulou J, et al. Utilization of a mutagenesis screen to generate mouse models of hyperaldosteronism. Endocrinology. 2011;152:326\u201331.","journal-title":"Endocrinology"},{"key":"2702_CR19","doi-asserted-by":"crossref","unstructured":"Chen L, Shi R, She X, Gu C, Chong L, Zhang L, et al. Mineralocorticoid receptor antagonist-mediated cognitive improvement in a mouse model of Alzheimer\u2019s type: possible involvement of BDNF-H2 S-Nrf2 signaling. Fundam Clin Pharmacol. 2020;34697-707.","DOI":"10.1111\/fcp.12576"},{"key":"2702_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.psyneuen.2012.09.011","volume":"38","author":"TC Wu","year":"2013","unstructured":"Wu TC, Chen HT, Chang HY, Yang CY, Hsiao MC, Cheng ML, et al. Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior. Psychoneuroendocrinology. 2013;38:871\u201383.","journal-title":"Psychoneuroendocrinology"},{"key":"2702_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100435","volume":"21","author":"F Francesca","year":"2022","unstructured":"Francesca F, Caitlin A, Sarah L, Robyn GL. Antroquinonol administration in animal preclinical studies for Alzheimer\u2019s disease (AD): a new avenue for modifying progression of AD pathophysiology. Brain Behav Immun Health. 2022;21:100435.","journal-title":"Brain Behav Immun Health"},{"key":"2702_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.steroids.2014.08.014","volume":"91","author":"EP Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez EP. Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis. Steroids. 2014;91:20\u201331.","journal-title":"Steroids"},{"key":"2702_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.psyneuen.2012.08.007","volume":"38","author":"AP Harris","year":"2013","unstructured":"Harris AP, Holmes MC, de Kloet ER, Chapman KE, Seckl JR. Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour. Psychoneuroendocrinology. 2013;38:648\u201358.","journal-title":"Psychoneuroendocrinology"},{"key":"2702_CR24","doi-asserted-by":"crossref","unstructured":"Giordano R, Pellegrino M, Picu A, Bonelli L, Balbo M, Berardelli R, et al. Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-Secretagogue-receptor modulation. ScientificWorldJournal. 2006;6:1\u201311.","DOI":"10.1100\/tsw.2006.09"},{"key":"2702_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.694758","volume":"12","author":"MF Rossier","year":"2021","unstructured":"Rossier MF. The cardiac mineralocorticoid receptor (MR): a therapeutic target against ventricular arrhythmias. Front Endocrinol. 2021;12:694758.","journal-title":"Front Endocrinol"},{"key":"2702_CR26","doi-asserted-by":"publisher","unstructured":"Brocca ME, Pietranera L, Meyer M, Lima A, Roig P, de Kloet ER, et al. Mineralocorticoid receptor associates with pro-inflammatory bias in the hippocampus of spontaneously hypertensive rats. J Neuroendocrinol. 2017;29. https:\/\/doi.org\/10.1111\/jne.12489. PMID: 28523794.","DOI":"10.1111\/jne.12489"},{"key":"2702_CR27","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1111\/bph.15835","volume":"179","author":"SN Paul","year":"2022","unstructured":"Paul SN, Wingenfeld K, Otte C, Meijer OC. Brain mineralocorticoid receptor in health and disease: from molecular signalling to cognitive and emotional function. Br J Pharmacol. 2022;179:3205\u201319.","journal-title":"Br J Pharmacol"},{"key":"2702_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/15622975.2022.2082524","volume":"24","author":"X Fan","year":"2023","unstructured":"Fan X, Zhao Z, Huang Z, Wu M, Wang D, Xiao J. Mineralocorticoid receptor agonist aldosterone rescues hippocampal neural stem cell proliferation defects and improves postoperative cognitive function in aged mice. World J Biol Psychiatry. 2023;24:149\u201361.","journal-title":"World J Biol Psychiatry"},{"key":"2702_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000215738","volume":"32","author":"X Cheng","year":"2009","unstructured":"Cheng X, Xu G. Association between aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis. Kidney Blood Press Res. 2009;32:128\u201340.","journal-title":"Kidney Blood Press Res"},{"key":"2702_CR30","first-page":"636","volume":"294","author":"JR Seckl","year":"2023","unstructured":"Seckl JR, Walker BR. 11\u03b2-hydroxysteroid dehydrogenase and the brain: not (yet) crystal clear. J Intern Med. 2023;294:636\u201350.","journal-title":"J Intern Med"},{"key":"2702_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s42003-025-08378-0","volume":"8","author":"EP Harris","year":"2025","unstructured":"Harris EP, Kandemir B, Jones SM, Alexander GM, Ward JM, Wang T, et al. Mineralocorticoid receptor knockout alters hippocampal CA2 neurons to become like those in CA1. Commun Biol. 2025;8:1037.","journal-title":"Commun Biol"},{"key":"2702_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2021.100369","volume":"15","author":"RH Oakley","year":"2021","unstructured":"Oakley RH, Whirledge SD, Petrillo MG, Riddick NV, Xu X, Moy SS, et al. Combinatorial actions of glucocorticoid and mineralocorticoid stress hormone receptors are required for preventing neurodegeneration of the mouse hippocampus. Neurobiol Stress. 2021;15:100369.","journal-title":"Neurobiol Stress"},{"key":"2702_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnbeh.2014.00026","volume":"8","author":"JP ter Horst","year":"2014","unstructured":"ter Horst JP, van der Mark M, Kentrop J, Arp M, van der Veen R, de Kloet ER, et al. Deletion of the forebrain mineralocorticoid receptor impairs social discrimination and decision-making in male, but not in female mice. Front Behav Neurosci. 2014;8:26.","journal-title":"Front Behav Neurosci"},{"key":"2702_CR34","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-19-0215","volume":"181","author":"B Lechner","year":"2019","unstructured":"Lechner B, Lechner K, Heinrich D, Adolf C, Holler F, Schneider H, et al. Medical treatment of primary aldosteronism. Eur J Endocrinol. 2019;181:R147\u2013R153.","journal-title":"Eur J Endocrinol"},{"key":"2702_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2003.08.034","volume":"43","author":"P Stella","year":"2004","unstructured":"Stella P, Bigatti G, Tizzoni L, Barlassina C, Lanzani C, Bianchi G, et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2004;43:265\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"2702_CR36","doi-asserted-by":"crossref","unstructured":"Preview : Journal Type Lee JE, Bae SY, Kim JY, Pyo HJ, Western Dialysis Physician Association (WDPA), Kwon YJ. Aldosterone synthase gene (CYP11B2) polymorphism in Korean end-stage renal disease patients on hemodialysis. Electrolyte Blood Press. 2009;7:67\u201372.","DOI":"10.5049\/EBP.2009.7.2.67"},{"key":"2702_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jash.2013.12.001","volume":"8","author":"V Fontana","year":"2014","unstructured":"Fontana V, de Faria AP, Barbaro NR, Sabbatini AR, Modolo R, Lacchini R, et al. Modulation of aldosterone levels by -344 C\/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. J Am Soc Hypertens. 2014;8:146\u201351.","journal-title":"J Am Soc Hypertens"},{"key":"2702_CR38","doi-asserted-by":"publisher","first-page":"e23322","DOI":"10.1097\/MD.0000000000023322","volume":"99","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhou M, Deng X, Ma Y, Jiang D. Correlation between CYP11B2 polymorphism and the risk of preeclampsia. Medicine. 2020;99:e23322.","journal-title":"Medicine"},{"key":"2702_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1456211","volume":"15","author":"A Nieckarz","year":"2024","unstructured":"Nieckarz A, Graff B, Burnier M, Marcinkowska AB, Narkiewicz K. Aldosterone in the brain and cognition: knowns and unknowns. Front Endocrinol. 2024;15:1456211.","journal-title":"Front Endocrinol"},{"key":"2702_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuroscience.2015.11.055","volume":"314","author":"HW Wang","year":"2016","unstructured":"Wang HW, Huang BS, Chen A, Ahmad M, White RA, Leenen FH. Role of brain aldosterone and mineralocorticoid receptors in aldosterone-salt hypertension in rats. Neuroscience. 2016;314:90\u2013105.","journal-title":"Neuroscience"},{"key":"2702_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1113\/expphysiol.1992.sp003622","volume":"77","author":"R Gerstberger","year":"1992","unstructured":"Gerstberger R, Sch\u00fctz H, Luther-Dyroff D, Keil R, Simon E. Inhibition of vasopressin and aldosterone release by atrial natriuretic peptide in conscious rabbits. Exp Physiol. 1992;77:587\u2013600.","journal-title":"Exp Physiol"},{"key":"2702_CR42","doi-asserted-by":"publisher","unstructured":"Deuter CE, Wei\u00df TS, Kuehl LK, Otte C, Wingenfeld K. Investigation of stress-induced cortisol effects on decision making after pharmacological mineralocorticoid or glucocorticoid receptor blockade. Pharmacopsychiatry. 2025. https:\/\/doi.org\/10.1055\/a-2646-7444.","DOI":"10.1055\/a-2646-7444"},{"key":"2702_CR43","doi-asserted-by":"publisher","first-page":"F559","DOI":"10.1152\/ajprenal.90399.2008","volume":"297","author":"JC Geerling","year":"2009","unstructured":"Geerling JC, Loewy AD. Aldosterone in the brain. Am J Physiol Renal Physiol. 2009;297:F559\u201376.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2702_CR44","first-page":"323","volume":"20","author":"S Suzuki","year":"2000","unstructured":"Suzuki S, Suzuki T, Tsubochi H, Koike K, Tateno H, Krozowski ZS, et al. Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas. Anticancer Res. 2000;20:323\u20138.","journal-title":"Anticancer Res"},{"key":"2702_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/ijms26020540","volume":"26","author":"N Ekman","year":"2025","unstructured":"Ekman N, Grossman AB, Nieckarz A, J\u0119drzejewski \u0141, Wolf J, Dworakowska D. Non-hypertensive effects of aldosterone. Int J Mol Sci. 2025;26:540.","journal-title":"Int J Mol Sci"},{"key":"2702_CR46","doi-asserted-by":"publisher","first-page":"T107","DOI":"10.1530\/JOE-16-0659","volume":"234","author":"S Ruhs","year":"2017","unstructured":"Ruhs S, Nolze A, H\u00fcbschmann R, Grossmann C. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107\u2013T124.","journal-title":"J Endocrinol"},{"key":"2702_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.pharmthera.2005.10.010","volume":"111","author":"O Sk\u00f8tt","year":"2006","unstructured":"Sk\u00f8tt O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL. Rapid actions of aldosterone in vascular health and disease\u2013friend or foe? Pharmacol Ther. 2006;111:495\u2013507.","journal-title":"Pharmacol Ther"},{"key":"2702_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1204598","volume":"2018","author":"A Cannavo","year":"2018","unstructured":"Cannavo A, Bencivenga L, Liccardo D, Elia A, Marzano F, Gambino G, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598.","journal-title":"Oxid Med Cell Longev"},{"key":"2702_CR49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/01.HYP.0000154365.30593.d3","volume":"45","author":"GE Callera","year":"2005","unstructured":"Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773\u20139.","journal-title":"Hypertension"},{"key":"2702_CR50","doi-asserted-by":"publisher","first-page":"H733","DOI":"10.1152\/ajpheart.00873.2011","volume":"302","author":"B Xue","year":"2012","unstructured":"Xue B, Beltz TG, Johnson RF, Guo F, Hay M, Johnson AK. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone\/NaCl-induced hypertension in mice. Am J Physiol Heart Circ Physiol. 2012;302:H733\u201341.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2702_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/ijms27020842","volume":"27","author":"E Mironova","year":"2026","unstructured":"Mironova E, Kvetnoy I, Balazovskaia S, Antonov V, Poyarkov S, Mazzoccoli G. Mitochondria and aging: redox balance modulation as a new approach to the development of innovative geroprotectors (Fundamental and Applied Aspects). Int J Mol Sci. 2026;27:842.","journal-title":"Int J Mol Sci"},{"key":"2702_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fendo.2020.00223","volume":"11","author":"A Vecchiola","year":"2020","unstructured":"Vecchiola A, Fuentes CA, Solar I, Lagos CF, Opazo MC, Mu\u00f1oz-Durango N, et al. Eplerenone implantation improved adipose dysfunction averting RAAS activation and cell division. Front Endocrinol. 2020;11:223.","journal-title":"Front Endocrinol"},{"key":"2702_CR53","doi-asserted-by":"publisher","first-page":"R276","DOI":"10.1152\/ajpregu.00280.2020","volume":"320","author":"G Jia","year":"2021","unstructured":"Jia G, Lockette W, Sowers JR. Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. Am J Physiol Regul Integr Comp Physiol. 2021;320:R276\u2013R286.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2702_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107166","volume":"217","author":"ZX Sun","year":"2025","unstructured":"Sun ZX, Xie F, Zhao Y, Wang X, Sun ZW, Qian LJ, et al. Exercise and the blood-brain barrier: mechanistic insights and therapeutic implications. Neurobiol Dis. 2025;217:107166.","journal-title":"Neurobiol Dis"},{"key":"2702_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.brainres.2016.02.034","volume":"1637","author":"QN Dinh","year":"2016","unstructured":"Dinh QN, Young MJ, Evans MA, Drummond GR, Sobey CG, Chrissobolis S. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016;1637:146\u201353.","journal-title":"Brain Res"},{"key":"2702_CR56","doi-asserted-by":"publisher","unstructured":"Ganesan V. The role of Renin-Angiotensin-Aldosterone system in the progression of cognitive dysfunction in chronic kidney disease patients with Alzheimer\u2019s disease. IntechOpen. 2021; https:\/\/doi.org\/10.5772\/intechopen.96048","DOI":"10.5772\/intechopen.96048"},{"key":"2702_CR57","doi-asserted-by":"crossref","unstructured":"Dinh QN, Vinh A, Lo C, Zhang DE, Galvao HB, Selvaraji S, et al. Hypertension promotes neuroinflammation, brain injury and cognitive impairment. Brain Behav Immun Health. 2025;48:101059.","DOI":"10.1016\/j.bbih.2025.101059"},{"key":"2702_CR58","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jalz.2018.06.2857","volume":"14","author":"GL Bowman","year":"2018","unstructured":"Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018;14:1640\u201350.","journal-title":"Alzheimers Dement"},{"key":"2702_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-260","volume":"9","author":"B Chantong","year":"2012","unstructured":"Chantong B, Kratschmar DV, Nashev LG, Balazs Z, Odermatt A. Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells. J Neuroinflammation. 2012;9:260. https:\/\/doi.org\/10.1186\/1742-2094-9-260.","journal-title":"J Neuroinflammation"},{"key":"2702_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34:15\u201327.","journal-title":"Am J Hypertens"},{"key":"2702_CR61","doi-asserted-by":"publisher","first-page":"17479","DOI":"10.18632\/oncotarget.8243","volume":"7","author":"W Ding","year":"2016","unstructured":"Ding W, Guo H, Xu C, Wang B, Zhang M, Ding F. Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. Oncotarget. 2016;7:17479\u201391.","journal-title":"Oncotarget"},{"key":"2702_CR62","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/antiox14040408","volume":"14","author":"R Wang","year":"2025","unstructured":"Wang R, Wang M, Du D, Shan Z, Bi L, Chen QH. Brain-targeted reactive oxygen species in hypertension: unveiling subcellular dynamics, immune cross-talk, and novel therapeutic pathways. Antioxidants. 2025;14:408.","journal-title":"Antioxidants"},{"key":"2702_CR63","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/ijms24032909","volume":"24","author":"YC Fang","year":"2023","unstructured":"Fang YC, Hsieh YC, Hu CJ, Tu YK. Endothelial dysfunction in neurodegenerative diseases. Int J Mol Sci. 2023;24:2909.","journal-title":"Int J Mol Sci"},{"key":"2702_CR64","doi-asserted-by":"crossref","unstructured":"Chen ZW, Hung CS, Wu VC, Lin YH., TAIPAI study group. Primary aldosteronism and cerebrovascular diseases. Endocrinol Metab. 2018;33:429\u201334.","DOI":"10.3803\/EnM.2018.33.4.429"},{"key":"2702_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/ajh\/hpae140","volume":"38","author":"ND Camarda","year":"2025","unstructured":"Camarda ND, Lu Q, Tesfu AF, Liu RR, Ibarrola J, Jaffe IZ. Mineralocorticoid receptor in endothelial cells contributes to vascular endothelial growth factor receptor inhibitor-induced vascular and kidney damage. Am J Hypertens. 2025;38:104\u201310.","journal-title":"Am J Hypertens"},{"key":"2702_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01910-5","volume":"22","author":"SB Shaikh","year":"2024","unstructured":"Shaikh SB, Balaya RDA, Dagamajalu S, Bhandary YP, Unwalla H, Prasad TSK, et al. A signaling pathway map of plasminogen activator inhibitor-1 (PAI-1\/SERPINE-1): a review of an innovative frontier in molecular aging and cellular senescence. Cell Commun Signal. 2024;22:544.","journal-title":"Cell Commun Signal"},{"key":"2702_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/a-2172-7228","volume":"56","author":"L Chen","year":"2024","unstructured":"Chen L, Adolf C, Reincke M, Schneider H. Salt and aldosterone - reciprocal and combined effects in preclinical models and humans. Horm Metab Res. 2024;56:99\u2013106.","journal-title":"Horm Metab Res"},{"key":"2702_CR68","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3921074","volume":"2020","author":"R Cai","year":"2020","unstructured":"Cai R, Hao Y, Liu YY, Huang L, Yao Y, Zhou MS. Tumor necrosis factor alpha deficiency improves endothelial function and cardiovascular injury in deoxycorticosterone acetate\/salt-hypertensive mice. Biomed Res Int. 2020;2020:3921074. https:\/\/doi.org\/10.1155\/2020\/3921074.","journal-title":"Biomed Res Int"},{"key":"2702_CR69","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1097\/HJH.0000000000000259","volume":"32","author":"S Chrissobolis","year":"2014","unstructured":"Chrissobolis S, Drummond GR, Faraci FM, Sobey CG. Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation. J Hypertens. 2014;32:1815\u201321.","journal-title":"J Hypertens"},{"key":"2702_CR70","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/antiox12040811","volume":"12","author":"L Sgarabotto","year":"2023","unstructured":"Sgarabotto L, Ravarotto V, Stefanelli LF, Cacciapuoti M, Davis PA, Nalesso F, et al. Oxidants and cardiorenal vascular remodeling-insights from rare genetic tubulopathies: Bartter\u2019s and Gitelman\u2019s syndromes. Antioxidants. 2023;12:811.","journal-title":"Antioxidants"},{"key":"2702_CR71","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1161\/HYPERTENSIONAHA.109.136226","volume":"54","author":"TA Kotchen","year":"2009","unstructured":"Kotchen TA. Sodium chloride and aldosterone: harbingers of hypertension-related cardiovascular disease. Hypertension. 2009;54:449\u201350.","journal-title":"Hypertension"},{"key":"2702_CR72","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1152\/jn.00221.2016","volume":"116","author":"CM Filley","year":"2016","unstructured":"Filley CM, Fields RD. White matter and cognition: making the connection. J Neurophysiol. 2016;116:2093\u2013104.","journal-title":"J Neurophysiol"},{"key":"2702_CR73","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/HYPERTENSIONAHA.118.12090","volume":"73","author":"J Jim\u00e9nez-Balado","year":"2019","unstructured":"Jim\u00e9nez-Balado J, Riba-Llena I, Abril O, Garde E, Penalba A, Ostos E, et al. Cognitive impact of cerebral small vessel disease changes in patients with hypertension. Hypertension. 2019;73:342\u20139.","journal-title":"Hypertension"},{"key":"2702_CR74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5853\/jos.2019.01844","volume":"22","author":"JS Kim","year":"2020","unstructured":"Kim JS, Lee S, Suh SW, Bae JB, Han JH, Byun S, et al. Association of low blood pressure with white matter hyperintensities in elderly individuals with controlled hypertension. J Stroke. 2020;22:99\u2013107.","journal-title":"J Stroke"},{"key":"2702_CR75","doi-asserted-by":"crossref","unstructured":"Reas ET, Laughlin GA, Hagler Jr DJ, Lee RR, Dale AM, McEvoy LK. et al. Age and sex differences in the associations of pulse pressure with white matter and subcortical microstructure. Hypertension. 2021;77:938\u201347.","DOI":"10.1161\/HYPERTENSIONAHA.120.16446"},{"key":"2702_CR76","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/IJGM.S499346","volume":"18","author":"W Chen","year":"2025","unstructured":"Chen W, Deng S, Li H, Zhao Y, Tian Y, Yuan Y. Alterations of white matter microstructure in primary aldosteronism patients with normal cognitive functioning using diffusion tensor imaging. Int J Gen Med. 2025;18:1089\u2013102.","journal-title":"Int J Gen Med"},{"key":"2702_CR77","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/jcm14134618","volume":"14","author":"J Herceg","year":"2025","unstructured":"Herceg J, Vukorepa G, Karanovi\u0107 \u0160tambuk S. Primary aldosteronism and cognitive dysfunction: a case-control study. J Clin Med. 2025;14:4618.","journal-title":"J Clin Med"},{"key":"2702_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/hr.2010.179","volume":"34","author":"S Yagi","year":"2011","unstructured":"Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y, et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res. 2011;34:74\u20138.","journal-title":"Hypertens Res"},{"key":"2702_CR79","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1530\/EC-19-0043","volume":"8","author":"L Engler","year":"2019","unstructured":"Engler L, Adolf C, Heinrich DA, Brem AK, Riester A, Franke A, et al. Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism. Endocr Connect. 2019;8:407\u201315.","journal-title":"Endocr Connect"},{"key":"2702_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105515","volume":"166","author":"L Scotti","year":"2021","unstructured":"Scotti L, Bassi L, Soranna D, Verde F, Silani V, Torsello A, et al. Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: a meta-analysis. Pharmacol Res. 2021;166:105515.","journal-title":"Pharmacol Res"},{"key":"2702_CR81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ajh\/hpu161","volume":"28","author":"I Hajjar","year":"2015","unstructured":"Hajjar I, Hart M, Mack W, Lipsitz LA. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. Am J Hypertens. 2015;28:319\u201325.","journal-title":"Am J Hypertens"},{"key":"2702_CR82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327\u201359.","journal-title":"Endocr J"},{"key":"2702_CR83","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2147\/NSS.S524831","volume":"17","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Huang L, Zhu L, Zhang X, Ji H, Niu D, et al. Association between fractional exhaled nitric oxide (FeNO) and cognitive function in patients with obstructive sleep apnea. Nat Sci Sleep. 2025;17:1603\u201314.","journal-title":"Nat Sci Sleep"},{"key":"2702_CR84","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/NSS.S376638","volume":"14","author":"W Xie","year":"2022","unstructured":"Xie W, Shu Y, Liu X, Li K, Li P, Kong L, et al. Abnormal spontaneous brain activity and cognitive impairment in obstructive sleep apnea. Nat Sci Sleep. 2022;14:1575\u201387.","journal-title":"Nat Sci Sleep"},{"key":"2702_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1373101","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Zhao W, Zhang W, Tian Z, Zhang Z, Lou Y, et al. Comparable cognitive impairment was detected in MACS and CS and alleviated after remission of hypercortisolism in MACS. Front Endocrinol. 2024;15:1373101.","journal-title":"Front Endocrinol"},{"key":"2702_CR86","doi-asserted-by":"publisher","DOI":"10.5646\/ch.2025.31.e42","volume":"31","author":"CJ Lee","year":"2025","unstructured":"Lee CJ, Park S. Amiloride: revisiting an old drug for resistant hypertension. Clin Hypertens. 2025;31:e42.","journal-title":"Clin Hypertens"},{"key":"2702_CR87","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrcardio.2010.161","volume":"7","author":"V Novak","year":"2010","unstructured":"Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686\u201398.","journal-title":"Nat Rev Cardiol"},{"key":"2702_CR88","doi-asserted-by":"publisher","first-page":"e003535","DOI":"10.1136\/openhrt-2025-003535","volume":"12","author":"IP Dewi","year":"2025","unstructured":"Dewi IP, Anggitama AM, Jati EB, Dewi KP. Comparative efficacy and safety of aldosterone synthase inhibitors in hypertension: a Bayesian network meta-analysis of randomised controlled rials. Open Heart. 2025;12:e003535.","journal-title":"Open Heart"},{"key":"2702_CR89","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Target-HTN investigators. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial. JAMA. 2023;330:1140\u201350.","journal-title":"JAMA"},{"key":"2702_CR90","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/CRD.0000000000000665","volume":"34","author":"JM Feldman","year":"2026","unstructured":"Feldman JM, Frishman WH, Aronow WS. Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors. Cardiol Rev. 2026;34:113\u20136.","journal-title":"Cardiol Rev"},{"key":"2702_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14676-4","volume":"11","author":"Z Liu","year":"2020","unstructured":"Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun. 2020;11:855.","journal-title":"Nat Commun"},{"key":"2702_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrneurol.2015.17","volume":"11","author":"H Umegaki","year":"2015","unstructured":"Umegaki H. Dementia: type 2 diabetes has a slow and insidious effect on cognition. Nat Rev Neurol. 2015;11:127\u20138.","journal-title":"Nat Rev Neurol"},{"key":"2702_CR93","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nrendo.2014.38","volume":"10","author":"MW Strachan","year":"2014","unstructured":"Strachan MW, Price JF. Diabetes. Cognitive decline and T2DM\u2013a disconnect in the evidence? Nat Rev Endocrinol. 2014;10:258\u201360.","journal-title":"Nat Rev Endocrinol"},{"key":"2702_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49430-7","volume":"15","author":"P Zhukovsky","year":"2024","unstructured":"Zhukovsky P, Tio ES, Coughlan G, Bennett DA, Wang Y, Hohman TJ, et al. Genetic influences on brain and cognitive health and their interactions with cardiovascular conditions and depression. Nat Commun. 2024;15:5207.","journal-title":"Nat Commun"},{"key":"2702_CR95","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28:844\u201351.","journal-title":"Nat Med"},{"key":"2702_CR96","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","volume":"7","author":"AL Byers","year":"2011","unstructured":"Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7:323\u201331.","journal-title":"Nat Rev Neurol"},{"key":"2702_CR97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1161\/HYPERTENSIONAHA.123.19943","volume":"81","author":"AH Hainsworth","year":"2024","unstructured":"Hainsworth AH, Markus HS, Schneider JA. Cerebral small vessel disease, hypertension, and vascular contributions to cognitive impairment and dementia. Hypertension. 2024;81:75\u201386.","journal-title":"Hypertension"},{"key":"2702_CR98","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/nu16091362","volume":"16","author":"T Ruskovska","year":"2024","unstructured":"Ruskovska T, Postolov F, Milenkovic D. Integrated analysis of genomic and genome-wide association studies identified candidate genes for nutrigenetic studies in flavonoids and vascular health: path to precision nutrition for (poly)phenols. Nutrients. 2024;16:1362.","journal-title":"Nutrients"},{"key":"2702_CR99","doi-asserted-by":"publisher","first-page":"E536","DOI":"10.1210\/jc.2013-3495","volume":"99","author":"B Howard","year":"2014","unstructured":"Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, Zhang L, et al. Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab. 2014;99:E536\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"2702_CR100","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/hr.2010.21","volume":"33","author":"GX Zhang","year":"2010","unstructured":"Zhang GX, Wang BJ, Ouyang JZ, Deng XY, Ma X, Li HZ, et al. Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism. Hypertens Res. 2010;33:478\u201384.","journal-title":"Hypertens Res"},{"key":"2702_CR101","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s43587-024-00693-1","volume":"4","author":"EA Frick","year":"2024","unstructured":"Frick EA, Emilsson V, Jonmundsson T, Steindorsdottir AE, Johnson ECB, Puerta R, et al. Serum proteomics reveal APOE-\u03b54-dependent and APOE-\u03b54-independent protein signatures in Alzheimer\u2019s disease. Nat Aging. 2024;4:1446\u201364.","journal-title":"Nat Aging"},{"key":"2702_CR102","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s43587-022-00241-9","volume":"2","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhou X, Wong HY, Ouyang L, Ip FCF, Chau VMN, et al. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-\u03b54 in female patients with Alzheimer\u2019s disease. Nat Aging. 2022;2:616\u201334.","journal-title":"Nat Aging"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02702-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:06:31Z","timestamp":1785881191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02702-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2702"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02702-9","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors declare no conflicts of interest related to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}